#21

Yes, and how does this relate to what I said?

#22

Ahh yes Vera Gorbunova’s pet. And yes that’s another interesting animal to gain longevity insights from.

#23

If it made worms immortal, what then?

#24

Far fetched, really but let’s play it or we can use that 200% life extension molecule in its place. The current approach is that when you uncover such a molecule extending worms lifespan then you test it on mice and if it goes well then you test it on dogs or marmosets and then finally on humans, This approach rests on foundation that what’s good for worms will be good for other more complex life forms too. in some proportionate measure at least. I’m sure that researchers don’t expect that a molecule that extends 200% lifespan in worms does so in equivalent measure in more complex animals such as mice. That indeed would be a shocking breakthrough. What I’m saying is that this top down approach is something but not a whole story. Without a top down approaches to augment it, it may take a very very long time even with AI to find a molecule that extends all humans lifespan substantially. And I don’t know about you, but I’m unwilling to wait couple of hundreds of years for that to happen.

#25

What are you suggesting?

1 Like
#26

It’s more “What is good for worms might be good for larger animals”. So if you have 100 compounds that increase lifespan in worms by 200% (and I’m sure Ora Biomedical will soon have that) then there’s maybe 10 of them that increase lifespan of Zebrafish or mice by more than 50%. This would already be a massive win. In a rather short period of time. (vs 20 years of ITP that “only” found rapamycin)

4 Likes
#27

I agree in principle that it is a game of odds. Further, I’m proposing a way to increase success odds that include both percentage of compounds that extend lifespan of mice and magnitudes of life extension. To ground this discussion, we have so far not found a way to increase max lifespan of mice by 50%. Rapamycin doesn’t do that, not even close. Only calorie restriction in some mice studies did that.
The simplified example of the top down approach would be e.g. to study greenland sharks and realize that their longevity is due to their never changing metabolism (+ who knows what, but lets put it aside for now) . Hence, as hypothesis we will come up with a compound of molecules that keeps metabolism steady day or night, meal or no meal. Next start testing it first on worms and then on mice, dogs etc. Testing on worms first would allow us to fine tune the compound and then if it works test it on more complex organisms. If the compound fails in dogs then modify it and retest quickly in worms. So in summary I really like the idea of rapid testing in worms but by itself it is in my opinion just too scattergun approach.

#28

see my response to @adssx here.

#29

Doable at home if it’s not a large compound with:

@Neo thoughts (since you talked about DIY obicetrapib iirc?)

3 Likes
#30

Think that was someone else? My current risk profile has me even avoiding ordering from India, etc.

#31

Nothing ever happens! :wink:

3 Likes
#32

The resources needed to pass those benchmarks are insane. When you think about how energy-efficient the human brain is in comparison it’s ridiculous.

2 Likes
#33

There are two-three years until 2027-2028 and a new halving of cost-to-compute (Moore’s law), more energy production, and algorithmic improvements etc. Even if somehow things didn’t get better here Moore’s law will make it all cheaper, and these models are probably not even fully utilized the way they are now.

2 Likes
#34

Maybe this can be the hype thread…

So now we have Deep Research for Pro subscribers, basically a research agent.
image

There’s so much alpha on the floor, imagine creating a prompt engineering industrial complex (AI is all about prompts).

image

Feeding each agent every one of your biomarker, then an overarching agent that integrates it all and doing things none of us have thought about yet (Move 37 in DeepMind go match). We are used to writing a prompt that’s like one or two sentences, this is not using these LLM’s fully – imagine internet search, database search, obscure papers and technical manuals from the 50’s and 60’s, with lots of reasoning token generation, and working on these tasks for days generating many orders of magnitude more tokens to be used by other agents. It’ll create programs and use frontier math to calculate and integrate things from first principles that’ll be unique in its application to the task at hand. It’s making my head spin. Limit is compute and energy.

When you take a look at its internal monologue (if available), it might be full of what appears to be gibberish to a human, using overly symbolic thinking like finding the center of the maze in a well kept garden. So we’ll resort to vibe coding and merely speaking and noticing the results over time, experimenting. We’ll be like Cypher in the Matrix

“Is that the Matrix? Yeah … There’s way too much information to decode the Matrix, you get used to it, I don’t even see the code. All I see is blond, brunette, redhead…”

m
m1920×800 125 KB

Ross Ulbricht Startup

But I don’t know, who knows…? Prediction markets aren’t that bullish on superlongevity yet…

7 Likes
#35

Europoors are banned from Deep Research for now :sob: I saw great improvement in the medical reasoning with o3 mini high so I can’t wait to try Deep Research…

2 Likes
#36

Far too early to conclude anything from that.

#37

We know the success rate in clinical trials. And companies such as BenevolentAI aren’t doing well.

#38

And the winner is: SenTcell. DOS inhibitor of sMAC. No you have never seen it mentioned before, but Disruptors of Sestrins DOS resolves the mechanistic cause of aging an intracellular complex made up of sestrins/AMPK/MAPK.

#39

Where is the evidence for this?

#40

Taking a look at this…Do you have any insight into this company?

Here’s what I could find.
https://sentcell.life/team/

Prof. Alessio Lanna, Ph.D. is the Founder of Sentcell. He obtained his Ph.D. from the University College London on Medical Research Council-Ph.D. studentship (2011-2016) and then continued as a Sir Henry Wellcome Trust Post-Doctoral Fellow at the University of Oxford (2016-2019). He currently holds an Honorary Professorship at UCL in recognition of paradigm shifting research in the field of cellular ageing and T lymphocyte senescence. He was the first to identify a hitherto unknown, multi druggable pro-ageing sMAC complex and the anti-ageing mechanism of telomere vesicle transfer at the immune synapse between APCs and T lymphocytes.

https://www.lifesciencesrevieweurope.com/sentcell

Is it possible to reverse the ageing clock in humans and extend the lifespan? This million-dollar question may finally have an answer.

The lifespan of a CD4+ T cell, which is at the pinnacle of the ageing clock, holds the key to human well-being. Reversing ageing and curing age-related diseases may now be possible by focusing on a single cell. T cell rejuvenating therapies that deliver immune protection over a lifetime offer boundless possibilities to respond to unmet medical needs.

Sentcell is taking charge of this revolution in human longevity by delaying ageing and improving lifespan with remarkably promising human rejuvenation and anti-ageing therapies.

The first company to implement fundamental medicine, Sentcell is developing first-class pharmaceutical classes to target pillars of ageing through selective T cell rejuvenation. No viable T cell rejuvenating therapies exist in the medical field, and the team is committed to bridge this gap with its premium platform.

More than 15 years of single-topic research and investigation of fundamental biology have culminated in Sentcell’s momentous discovery of the Sestrin MAP kinase activation complex (sMAC), as a multi-druggable longevity target in 2017. A rational design focused on a single pathway characterizes its rejuvenation therapies.

Setting Sentcell ahead of the competition is its approach based on unique and previously unknown anti-ageing biology to design innovative compounds. They modulate the immune state, particularly in T Cells, to produce broader systemic effects.

“We focus all our efforts on helping humanity break the chains of ageing and disease,” says Dr. Alessio Lanna, CEO and Chairman of Sentcell.

Prof. Alessio Lanna’s 2 scientific papers:

https://www.researchsquare.com/article/rs-5180379/v1

And an article about skin cream - Telogift by THEINFINUM.
“This discovery set the stage for Telogift, the world’s first cream to harness natural telomere transfer reactions for skin rejuvenation.”

https://nyweekly.com/business/theinfinums-prof-alessio-lanna-ph-d-skincares-revolution/

1 Like